Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC Update - May 2018

The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.

Naltrexone / bupropion (Mysimba®) has been rejected for use as an adjunct to a reduced-calorie diet and increased physical activity, for the management of weight in adult patients (≥18 years) with an initial Body Mass Index (BMI) of:

  • ≥ 30 kg/m² (obese), or
  • ≥ 27 kg/m² to < 30 kg/m² (overweight) in the presence of one or more weight-related co-morbidities (e.g., type 2 diabetes, dyslipidaemia, or controlled hypertension)

The manufacturer failed to make a submission for this indication.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC Update - May 2018' on Email Share 'SMC Update - May 2018' on Delicious Share 'SMC Update - May 2018' on Digg Share 'SMC Update - May 2018' on Facebook Share 'SMC Update - May 2018' on reddit Share 'SMC Update - May 2018' on StumbleUpon Share 'SMC Update - May 2018' on Twitter

atomic-wealth

No Comments to “SMC Update - May 2018”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.

atomic-wealth
fond-illness
summer